Evidence map›Paper›PMID 38888787›Full record

ReviewMethods in molecular biology (Clifton, N.J.)2024

RNA-Based Vaccines and Therapeutics Against Intracellular Pathogens.

Naga Suresh Kola, Dhruv Patel, Aneesh Thakur

Abstract readReview
PubMed Publisher
In one paragraph

Review in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Naga Suresh KolaVaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK, Canada.
Dhruv PatelVaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK, Canada.
Aneesh ThakurVaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK, Canada. aneesh.thakur@usask.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA-based vaccines have sparked a paradigm shift in the treatment and prevention of diseases by nucleic acid medicines. There has been a notable surge in the development of nucleic acid therapeutics and vaccines following the global approval of the two messenger RNA-based COVID-19 vaccines. This growth is fueled by the exploration of numerous RNA products in preclinical stages, offering several advantages over conventional methods, i.e., safety, efficacy, scalability, and cost-effectiveness. In this chapter, we provide an overview of various types of RNA and their mechanisms of action for stimulating immune responses and inducing therapeutic effects. Furthermore, this chapter delves into the varying delivery systems, particularly emphasizing the use of nanoparticles to deliver RNA. The choice of delivery system is an intricate process involved in developing nucleic acid medicines that significantly enhances their stability, biocompatibility, and site-specificity. Additionally, this chapter sheds light on the current landscape of clinical trials of RNA therapeutics and vaccines against intracellular pathogens.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2AnimalsHumansmRNA VaccinesNanoparticlesRNACOVID-19 VaccinesmRNA VaccinesRNAClinical trialsCRISPR-based gene editingIntracellular infectionsLipid and polymer-based delivery systemsmRNA vaccinesRNA-based therapeuticsRNA delivery systemsRNA interferenceRNA vaccinesViral infections

Identifiers

PMID38888787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.